By Christy Santhosh and Kamal Choudhury Jan 22 (Reuters) - Abbott forecast current-quarter profit below estimates after ...

Jan 22 (Reuters) - Abbott forecast current-quarter profit below estimates after missing Wall Street expectations for ...

Abbott guided first-quarter earnings below expectations after promotions weighed on nutrition sales and margins.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the company’s shares.

Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22, as the market digested weaknesses from its fourth-quarter and full-year earnings report. | Abbott Laboratories saw ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott Laboratories (ABT) stock falls as underperformance in the company's Nutrition segment leads it to record lower than expected Q4 sales. Read more here.

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Abbott's fourth quarter revenue missed expectations in its devices, diagnostics and nutrition segments, while staying in line for its established pharmaceutical business.

Abbott missed analysts’ profit expectations for Q4 2025, yet the company’s full year financials were buoyed by strong ...